DiaMedica Therapeutics Inc
For the period ended May 15, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 15, 2025 · Filed May 15, 2025
Use the contents to explore the available documents and sections.
Contents
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|---|
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|---|
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|---|
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Voting common shares, no par value per share | DMAC | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
DiaMedica Therapeutics Inc. (the “Company”) held its 2025 Annual General Meeting of Shareholders (the “2025 AGM”) on May 15, 2025. As of the close of business on March 18, 2025, the record date for the 2025 AGM, there were 42,855,660 voting common shares, no par value, of the Company (“Common Shares”) outstanding and entitled to vote at the 2025 AGM. Each Common Share was entitled to one vote. Shareholders holding an aggregate of 19,344,190 Common Shares entitled to vote at the 2025 AGM, representing 45.1% of the outstanding Common Shares as of the record date, and which constituted a quorum thereof, were present in person or represented by proxy at the 2025 AGM.
At the 2025 AGM, the Company’s shareholders considered three voting proposals, each of which is described in detail in the Company’s definitive proxy statement for the 2025 AGM filed with the United States Securities and Exchange Commission on March 28, 2025.
The final voting results of each voting proposal brought before a vote of the Company’s shareholders at the 2025 AGM are set forth below:
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.